Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities
Oculis (OCS) announced a notification concerning the vesting and settlement of restricted stock units (RSUs) previously granted to a director.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Oculis (OCS) announced a notification concerning the vesting and settlement of restricted stock units (RSUs) previously granted to a director.
The notification identifies Arshad Khanani and records an RSU vest dated 29 November 2025.
Details
News Market Reaction – OCS
On Dec 4, the first trading day after this news, OCS closed 3.74% above the previous close.
Data tracked by StockTitan Argus for the Dec 4 session.
Key Figures
- Registered resale shares
- 494,259 shares
- Form F-3 warrant-related resale registration
- Warrant exercisable now
- 59,310 shares
- Currently exercisable portion of warrant under Form F-3
- Warrant exercise price
- $12.17
- Exercise price for 361,011 warrant shares
- Warrant exercise price
- $18.64
- Exercise price for 133,248 warrant shares
- Max cash from warrant
- $6,877,246.59
- If warrant fully exercised for 494,259 shares
- Shares outstanding
- 52,374,811 shares
- Ordinary shares outstanding as of Sept 30, 2025
- Underwritten offering size
- 4,691,358 shares
- Ordinary shares offered at $20.25 per share
- Registered direct sale
- 740,740 shares
- Registered direct offering at $20.25 per share
Historical Context
-
Disclosure of RSU vesting and settlement for director Arshad Khanani.
-
Notification of RSU vesting and settlement for a company director.
-
Positive FDA meeting enabling PIONEER registrational program for Privosegtor.
-
Board member purchase of ordinary shares reported in managers’ transaction notice.
-
Positive Phase 2 ACUITY trial data for Privosegtor in acute optic neuritis.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
rsus financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
ZUG, Switzerland, Dec. 03, 2025 (GLOBE NEWSWIRE) -- The attached notification relates to the vesting and settlement of RSUs previously granted to a director of the Company.
Attachment
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.